---
reference_id: "PMID:29186568"
title: "Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis."
authors:
- Guerrini-Rousseau L
- Dufour C
- Varlet P
- Masliah-Planchon J
- Bourdeaut F
- Guillaud-Bataille M
- Abbas R
- Bertozzi AI
- Fouyssac F
- Huybrechts S
- Puget S
- Bressac-De Paillerets B
- Caron O
- Sevenet N
- Dimaria M
- Villebasse S
- Delattre O
- Valteau-Couanet D
- Grill J
- Brugières L
journal: Neuro Oncol
year: '2018'
doi: 10.1093/neuonc/nox228
content_type: abstract_only
---

# Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, cancer risk, and prognosis.
**Authors:** Guerrini-Rousseau L, Dufour C, Varlet P, Masliah-Planchon J, Bourdeaut F, Guillaud-Bataille M, Abbas R, Bertozzi AI, Fouyssac F, Huybrechts S, Puget S, Bressac-De Paillerets B, Caron O, Sevenet N, Dimaria M, Villebasse S, Delattre O, Valteau-Couanet D, Grill J, Brugières L
**Journal:** Neuro Oncol (2018)
**DOI:** [10.1093/neuonc/nox228](https://doi.org/10.1093/neuonc/nox228)

## Content

1. Neuro Oncol. 2018 Jul 5;20(8):1122-1132. doi: 10.1093/neuonc/nox228.

Germline SUFU mutation carriers and medulloblastoma: clinical characteristics, 
cancer risk, and prognosis.

Guerrini-Rousseau L(1), Dufour C(1), Varlet P(2), Masliah-Planchon J(3)(4), 
Bourdeaut F(3)(5)(6), Guillaud-Bataille M(7), Abbas R(8)(9), Bertozzi AI(10), 
Fouyssac F(11), Huybrechts S(12), Puget S(13), Bressac-De Paillerets B(7), Caron 
O(3)(4)(14), Sevenet N(15)(16)(17), Dimaria M(14), Villebasse S(14), Delattre 
O(1), Valteau-Couanet D(1), Grill J(18), Brugières L(1).

Author information:
(1)Département de Cancérologie de l'Enfant et de l'Adolescent, Gustave Roussy, 
Université Paris-Saclay, Villejuif, France.
(2)Service de neuropathologie, Hôpital Sainte-Anne, Université Paris Descartes, 
Paris, France.
(3)PSL Research University, INSERM U830 Génétique et Biologie des Cancers 
Institut Curie, Paris, France.
(4)Unité de génétique somatique, SIREDO pediatric oncology center, Institut 
Curie, Paris, France.
(5)Département d'oncologie Pédiatrique adolescents Jeunes Adultes, Institut 
Curie, Paris, France, SIREDO pediatric oncology center, Institut Curie, Paris, 
France.
(6)Institut Curie SIRIC - Laboratoire de Recherche Translationnelle en Oncologie 
Pédiatrique, Institut Curie, Paris, France.
(7)Département de Biologie et Pathologie Médicales, Gustave Roussy, Université 
Paris-Saclay, Villejuif, France.
(8)INSERM U1018, CESP, Université Paris-Sud, Université Paris-Saclay, Villejuif, 
France.
(9)Service de Biostatistique et d'Epidémiologie, Gustave Roussy, Université 
Paris-Saclay, Villejuif, France.
(10)Unité d' Hémato-Immuno-Oncologie pédiatrique, CHU Toulouse, Toulouse, 
France.
(11)Onco-hématologie pédiatrique, Hôpital d'Enfants, CHU Nancy, Nancy, France.
(12)Hematology-Oncology Unit, Hôpital Universitaire des Enfants Reine Fabiola, 
ULB Université libre de Bruxelles, Brussels, Belgium.
(13)Service de neurochirurgie pédiatrique, Hôpital Necker-Enfants malades, 
Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
(14)Département de Médecine Oncologique, Gustave Roussy, Université 
Paris-Saclay, Villejuif, France.
(15)Laboratoire de génétique moléculaire, Département de bio-pathologie, 
Institut Bergonié, Bordeaux, France.
(16)INSERM U1218, Université de Bordeaux, Bordeaux, France.
(17)UFR des Sciences Pharmaceutiques, Université de Bordeaux, Bordeaux, France.
(18)Unité Mixte de Recherche 8203 du Centre National de la Recherche 
Scientifique, Université Paris-Saclay, Villejuif, France.

BACKGROUND: Germline mutations of suppressor of fused homolog (SUFU) predispose 
to sonic hedgehog (SHH) medulloblastoma. Germline SUFU mutations have been 
reported in nevoid basal cell carcinoma syndrome (NBCCS), but little is known 
about the cancer risk and clinical spectrum.
METHODS: We performed a retrospective review of all patients with 
medulloblastoma and a germline SUFU mutation in France.
RESULTS: Twenty-two patients from 17 families were identified with 
medulloblastoma and a germline SUFU mutation (median age at diagnosis: 16.5 mo). 
Macrocrania was present in 20 patients, but only 5 met the diagnostic criteria 
for NBCCS. Despite treatment with surgery and chemotherapy, to avoid 
radiotherapy in all patients except one, the outcome was worse than expected for 
SHH medulloblastoma, due to the high incidence of local relapses (8/22 patients) 
and second malignancies (n = 6 in 4/22 patients). The 5-year progression-free 
survival and overall survival rates were 42% and 66%. Mutations were inherited 
in 79% of patients, and 34 additional SUFU mutation carriers were identified 
within 14 families. Medulloblastoma penetrance was incomplete, but higher than 
in Patched 1 (PTCH1) mutation carriers. Besides medulloblastoma, 19 other tumors 
were recorded among the 56 SUFU mutation carriers, including basal cell 
carcinoma (BCC) in 2 patients and meningioma in 3 patients.
CONCLUSION: Germline SUFU mutations strongly predispose to medulloblastoma in 
the first years of life, with worse prognosis than usually observed for SHH 
medulloblastoma. The clinical spectrum differs between SUFU and PTCH1 mutation 
carriers, and BCC incidence is much lower in SUFU mutation carriers. The optimal 
treatment of SUFU mutation-associated medulloblastoma has not been defined.

DOI: 10.1093/neuonc/nox228
PMCID: PMC6280147
PMID: 29186568 [Indexed for MEDLINE]